TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

NCT00161967 | Completed Phase 4 DMC

• 1 other identifier: 700401
• Study Type: interventional
• Target: 375
• Locations: 3 countries
• Sites: 3

Brief Summary

The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months after completion of primary immunization with FSME-IMMUN 0.25 ml (3 vaccinations during the predecessor study 209), as well as the immune response to a booster vaccination with FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml administered 36 months after the third vaccination (in Study 209). Protocol amendment of October 2006: The study has been prolonged for children and adolescents who still showed highly positive TBE virus antibody concentrations at approximately 3 years after the third vaccination and therefore did not receive a booster vaccination at this time point. Further follow-up of TBE antibody persistence is now included for these subjects at 46 and 58 months after the third vaccination (in Study 209), as well as a booster vaccination offered at either 48 or 60 months after the third vaccination (in Study 209), depending on individual TBE antibody levels.

Conditions

Encephalitis, Tick-Borne

Keywords

tick-borne encephalitis

Outcome Measures

Primary Outcomes (1)

• Seropositivity rate measured by ELISA and/or NT according to Adner et al., 2001 at each available time point after the third vaccination in study 209 and separately at each available time point after the booster vaccination in this study

  TBE virus antibody tests at pre-determined intervals with the last test at 21-35 days after the booster vaccination in this study

Interventions

Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) BIOLOGICAL

Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.

Eligibility Criteria

• Age: 3 Years - 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Participated in Baxter study 209 and:
• They and/or their parents / legal guardians understand the nature of the study and agree to its provisions
• Written informed consent is available from the parents / legal guardians according to national law
• Written informed assent is available from the child/adolescent according to age and capacity of understanding
• They received the third vaccination with FSME-IMMUN 0.25 ml during the course of Baxter study 209
• Blood was drawn after their third vaccination during the course of Baxter study 209
• They showed an ELISA concentration \> 126 VIE U/ml and / or a NT titer \>=10 after the third vaccination in Baxter study 209
• They or their parents / legal guardians agree to keep a Subject Diary

You may not qualify if:

• Received any TBE vaccination since their third vaccination with FSME-IMMUN 0.25 ml
• Have a history of infection with or vaccination against other flaviviruses (Dengue fever, yellow fever and / or Japanese B-encephalitis virus) since their third vaccination with FSME-IMMUN 0.25 ml
• Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since their third vaccination with FSME-IMMUN 0.25 ml
• Received a blood transfusion or immunoglobulins within 30 days of the first and second blood draw (as applicable)
• Have a known or suspected problem with drug or alcohol abuse (\> 4 liters wine / week or equivalent level of other alcoholic beverages)
• Have participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies)
• Subjects will not be eligible for booster vaccination if they:
• Are not clinically healthy, (i.e. the physician would have reservations vaccinating with a TBE vaccine outside the scope of a clinical trial)
• Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions
• Have shown an allergic reaction to one of the components of the vaccine since their third vaccination in Baxter study 209
• Have donated blood or plasma within 30 days of the booster vaccination if female of childbearing potential - are pregnant or breastfeeding before the booster vaccination (positive pregnancy test result at the medical examination before the booster vaccination)
• Are simultaneously participating in another clinical trial including administration of an investigational product within six weeks prior to the booster vaccination until the end of the study
• Subjects who received any vaccination within 4 weeks prior to the booster vaccination will not be vaccinated until an interval of four weeks has passed.
• If subjects received antipyretics within 4 hours prior to the intended TBE vaccination, the vaccination should be performed at a later time.
• Females of childbearing potential will only be vaccinated if they agree to employ adequate birth control measures from 4 weeks before the booster vaccination until the end of the study.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (3)

Grieskirchner Strasse 17

Wels, Upper Austria, 4600, Austria

Location

Hauptstrasse 240

Kehl, 77694, Germany

Location

Niepubliczny ZOZ

Zamość, 22-400, Poland

Location

MeSH Terms

Conditions

Encephalitis, Tick-Borne

Interventions

Vaccines

Condition Hierarchy (Ancestors)

Encephalitis, Arbovirus; Encephalitis, Viral; Central Nervous System Viral Diseases; Central Nervous System Infections; Infections; Infectious Encephalitis; Arbovirus Infections; Vector Borne Diseases; Tick-Borne Diseases; Virus Diseases; RNA Virus Infections; Flavivirus Infections; Flaviviridae Infections; Encephalitis; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuroinflammatory Diseases

Intervention Hierarchy (Ancestors)

Biological Products; Complex Mixtures

Study Officials

• Baxter BioScience Investigator

  Baxter BioScience

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 8, 2005
• First Posted: September 13, 2005
• Study Start: May 1, 2005
• Primary Completion: July 1, 2008
• Study Completion: November 1, 2008
• Last Updated: May 21, 2015

Record last verified: 2015-05

Locations

PL (1); AU (1); DE (1)